The validity and integrity of the patent issuing system is vital to the success of our economy. Government agencies are responsible for carrying out legally mandated processes related to patents, including patent reviews and examinations. Their role is to grant patents to inventions that meet the criteria set forth in patent laws while upholding the principles of transparency and quality to maintain the integrity of the patent system. They play a crucial role in promoting innovation and protecting the intellectual property rights of inventors and businesses in their respective nation. The primary goal is to establish a robust system of checks and balances ensuring the proper issuance and long-term maintenance/record of patent filings.
Fast, Efficient, Reliable
With hundreds of thousands of patent filings each year, government agencies are reliant on fast, reliable, and efficient solutions to maximize their productivity while maintaining their legal quality of patent standards. The IP Suite provides a robust set of services, analytics, and solutions that meet the rigorous standards of government agencies around the world.
Patent Process
When inventors or companies apply for a patent, they submit detailed descriptions and claims of their inventions to their appropriate government agency. These applications are then subjected to a thorough examination process conducted by patent examiners employed by the agency. Patent examiners review patent applications to ensure they meet the legal requirements for patentability, which typically include novelty, non-obviousness, and utility. They also check for proper documentation, clarity, and compliance with patent laws and regulations. Part of the examination process involves conducting a search for prior art, which refers to existing patents, publications, and knowledge relevant to the invention in question. The goal is to determine whether the invention is genuinely novel and non-obvious.
Review & Examination
If disputes arise between the applicant and the government agency regarding patentability, they can go through various legal procedures, including requesting reexamination or appealing the agency’s decisions to the Patent Trial and Appeal Board (PTAB) or the Federal Courts. Patent applications and granted patents are public records, and they are made accessible to the public. This transparency promotes innovation and allows others to build upon existing knowledge.
Tailored Solutions
InnovationQ+™
InnovationQ+ is an innovation and IP decision support workflow solution packed with powerful data analytics and competitive insights that enable informed, rapid decisions throughout the lifecycle—reducing costs, maximizing ROI, and accelerating innovation.
IP Services
Our world-class Professional Services team speeds up your innovation workflows, completing essential research, analytics, editing, and reporting tasks using industry-leading expertise and our AI-driven solutions.
Patent & IP News
Get a Preview of Exciting New Features in the IP Suite at AI Masters 2024
Explore AI at IP Watchdog AI Masters 2024! Join the event for discussions on AI and ML. As proud sponsors, we’ll be showcasing innovations from March 4-6, 2024, in Ashburn, Virginia. Connect with us, preview exclusive features, and dive into the future of AI in intellectual property.
How the New USPTO Pre-Application Assessment Program Only Reinforces the Need for Integrated & Intelligent Patent Evaluation Software
With a steady increase in patent submission rate and added strain on the patent review and approval system, the USPTO has announced plans to launch a new pre-application review program called the “Pre-Prosecution Pilot” as part of its continuing commitment to expand access to the innovation ecosystem and support under resourced inventors.
How Apple, the Largest Company in the World, Plays the Patent Infringement Gamble
In recent news, Apple has faced a patent infringement suit regarding the blood oxygen technology in two of its Apple Watch Series models resulting in a halt in sales of their watch models. The halt in sales comes after the International Trade Commission ruled that these two models’ use of blood oxygen tracking violated a patent from health technology company Masimo.